Literature DB >> 24747563

Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.

Weibin Wu1, Xijun Liu1, Xiaomin Peng1, Ruyi Xue2, Lingling Ji1, Xizhong Shen2, She Chen3, Jianxin Gu1, Si Zhang4.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases, and the pathogenesis is still not well known. The farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily and plays an essential role in maintaining bile acid and lipid homeostasis. In this study, we study the role of FXR in the pathogenesis of NFALD. We found that FXR deficient (FXR(-/-)) mice fed methionine- and choline-deficient (MCD) diet had higher serum ALT and AST activities and lower hepatic triglyceride levels than wild-type (WT) mice fed MCD diet. Expression of genes involved in inflammation (VCAM-1) and fibrosis (α-SMA) was increased in FXR(-/-) mice fed MCD diet (FXR(-/-)/MCD) compared to WT mice fed MCD diet (WT/MCD). Although MCD diet significantly induced hepatic fibrosis in terms of liver histology, FXR(-/-)/MCD mice showed less degree of hepatic steatosis than WT/MCD mice. Moreover, FXR deficiency synergistically potentiated the elevation effects of MCD diet on serum and hepatic bile acids levels. The super-physiological concentrations of hepatic bile acids in FXR(-/-)/MCD mice inhibited the expression of genes involved in fatty acid uptake and triglyceride accumulation, which may be an explanation for less steatosis in FXR(-/-)/MCD mice in contrast to WT/MCD mice. These results suggest that hepatic bile acids accumulation could override simple steatosis in hepatic injury during the progression of NAFLD and further emphasize the role of FXR in maintaining hepatic bile acid homeostasis in liver disorders and in hepatic protection.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FXR; Fibrosis; Hepatic steatosis; Inflammation; NFALD

Mesh:

Substances:

Year:  2014        PMID: 24747563     DOI: 10.1016/j.bbrc.2014.04.048

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  FXR Agonists: From Bench to Bedside, a Guide for Clinicians.

Authors:  Ahmad Samer Alawad; Cynthia Levy
Journal:  Dig Dis Sci       Date:  2016-10-12       Impact factor: 3.199

Review 2.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

Review 3.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

Review 4.  Recent advances in the development of farnesoid X receptor agonists.

Authors:  Ahmad H Ali; Elizabeth J Carey; Keith D Lindor
Journal:  Ann Transl Med       Date:  2015-01

5.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

6.  Activation of FXR protects against renal fibrosis via suppressing Smad3 expression.

Authors:  Kai Zhao; Jialin He; Yan Zhang; Zhizhen Xu; Haojun Xiong; Rujun Gong; Song Li; Shan Chen; Fengtian He
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

7.  Chemoproteomic Profiling of Bile Acid Interacting Proteins.

Authors:  Shentian Zhuang; Qiang Li; Lirong Cai; Chu Wang; Xiaoguang Lei
Journal:  ACS Cent Sci       Date:  2017-05-05       Impact factor: 14.553

8.  iPla2β Deficiency Suppresses Hepatic ER UPR, Fxr, and Phospholipids in Mice Fed with MCD Diet, Resulting in Exacerbated Hepatic Bile Acids and Biliary Cell Proliferation.

Authors:  Yanan Ming; Xingya Zhu; Sabine Tuma-Kellner; Alexandra Ganzha; Gerhard Liebisch; Hongying Gan-Schreier; Walee Chamulitrat
Journal:  Cells       Date:  2019-08-12       Impact factor: 6.600

Review 9.  Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

Authors:  Hiroshi Fukui
Journal:  Diseases       Date:  2019-11-12

10.  Dietary Cholic Acid Exacerbates Liver Fibrosis in NASH Model of Sprague-Dawley Rats Fed a High-Fat and High-Cholesterol Diet.

Authors:  Mayuko Ichimura-Shimizu; Shiro Watanabe; Yuka Kashirajima; Ami Nagatomo; Hitomi Wada; Koichi Tsuneyama; Katsuhisa Omagari
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.